Adrian Newman-Tancredi, PhD, DSc, will present at the forthcoming World Orphan Drug Congress to be held November 12-14, 2014 in Brussels, Belgium. Dr. Newman-Tancredi has been invited in his capacity as Chief Scientific Officer of Neurolixis to chair the session on "Innovation in the Orphan Drug Sector".
Neurolixis is developing a clinical candidate, NLX-101, as a treatment for Rett syndrome, a serious orphan disorder that affects about 30 000 girls in Europe and North America. Investigation of the physiological effects of NLX-101 is being conducted by Dr. Abdala Sheik at the University of Bristol in the laboratory of Prof. Julian Paton with support from the International Rett Syndrome Foundation and the Rett Syndrome Research Trust (see previous press release).
For full details of the World Orphan Drug Congress program see the meeting website.